Erratum: Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature (Leukemia (2007) 10.1038/sj.leu.2404934);Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature [16]

Leukemia

Volumn 22, Issue 2, 2008, Pages 459-461

  Chng, W J ^a   Kuehl, W M ^b   Bergsagel, P L ^a   Fonseca, R ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 7P; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG MEGADOSE; FISHER EXACT TEST; GENE DELETION; GENE EXPRESSION PROFILING; HEREDITY; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LETTER; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 39149123808     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405089     Document Type: Erratum

References (9)

1. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
2. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2006; 109: 2276-2284.
3. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-2989.
4. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
5. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
6. Xiong W, Zhan F, Huang Y, Barlogie B, Shaughnessy Jr JD. TP53 gene expression, correlated with 17p13 deletion, is a significant and independent adverse prognostic factor in multiple myeloma treated with high-dose therapy and auto-transplants. ASH Annu Meeting Abstr 2006; 108: 3394.
7. Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007. Prepublished online 12 Jul 2007; doi:10.1038/sj.leu.2404832.
8. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-2948.
9. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039-4046.